| Literature DB >> 16439844 |
Leif Groop1, Mikael Segerlantz, Margareta Bramnert.
Abstract
Adult growth hormone deficiency (GHD) is a multifactorial disorder in which pituitary dysfunction associated with pituitary adenomas or their treatment plays a major role. The introduction of recombinant growth hormone (GH) for the treatment of GHD has opened up new treatment avenues but has also raised concerns about possible untoward long-term metabolic effects of GH, such as the potential effect of GH on insulin sensitivity and a deterioration in glucose tolerance. Research has shown that GH induces insulin resistance by the stimulation of lipolysis and a concomitant switch from oxidation of glucose to oxidation of lipids, during both acute and chronic treatment. However, although this is a consistent effect of GH therapy, it does not mean per se that it leads to abnormal glucose tolerance and diabetes mellitus. This article discusses this and other potential long-term metabolic effects of GH, and raises a number of questions to be addressed by future research. Copyright (c) 2005 S. Karger AG, BaselEntities:
Mesh:
Substances:
Year: 2006 PMID: 16439844 DOI: 10.1159/000089317
Source DB: PubMed Journal: Horm Res ISSN: 0301-0163